Sustainable development is a mirror of our future

Today, Hemofarm is recognized as one of the leaders of sustainable development in Serbia and the region, but also as the strongest link in the sustainable development of STADA Group. How important the Serbian market is for STADA Group is the best indicator of the investment of over 400 million euros, which so far invested in the Hemofarm company.

Dr. Ronald Seeliger, CEO of the Hemofarm Group, talked about Hemofarm's growth and development, investments, as well as the sustainable plan for the future in an interview for the ‘Politika’ newspapers.

‘Hemofarm is the leading generic pharmaceutical company in Serbia and the region with quality products that have been trusted for 62 years and having a portfolio with newest generation medication and OTC. Today, Hemofarm strives to contribute to strengthening the reputation of the entire Group, thereby actively building a reputation among customers, users, and suppliers‘, says Dr. Ronald Seeliger, CEO of Hemofarm.

How important is the Serbian market for STADA Group?

‘STADA Group has a business tradition of more than a century. Do not forget that STADA is one of the largest German investors in Serbia. The best indicator of how important the Serbian market is for STADA Group are the over 400 million euros, which have been invested so far in the Hemofarm. Serbia and the entire region of the Western Balkans are highly relevant and key market for us, so we constantly strive to improve our business and strengthen our leadership position.

I would say that we confirmed our position with the recent 10th Report on sustainable development, under the slogan ‘Guardian of a Sustainable Present and a More Certain Future‘. Hemofarm has a well-rounded and modern portfolio, quality management and certification as a confirmation of quality, top research and sustainable development.‘

What were your expectations, and what results did you achieve in 2022?

‘Serbia is a country full of opportunities for business development. Bearing in mind the changing economic environment and that we always strive to be even better, the results we achieved exceeded the expectations and plans for the previous period. During 2022, we simply continued to do what we normally do. We have a clear path, we are growing, and we are proud to provide even more suitable medicines for people, because I think every patient deserves to have the right medicine.

Today, Hemofarm is recognized as one of the leaders of sustainable development in Serbia and the region, but also as the strongest link in the sustainable development of the STADA Group. However, sustainability is not only about business and good business results, but about trying to somehow reduce the consumption of all the resources we use. Behind us is a decade of reporting on sustainable development, during which we invested a lot of effort and commitment to contribute to making the world a better place to live. We worked to educate and motivate Hemofarm employees, their families, business partners, consumers, and the community to understand and apply the principles of sustainable development in their daily lives.

On the other hand, this year was also marked by investments in Hemofarm, so over 25 million EUR were invested in new projects this year alone, and we recently opened a new line at our plant in Sabac. By investing 10 million euros for the reconstruction and acquisition of new production equipment, we have expanded our portfolio and in 2023 we will start production of the world-famous brand ‘Nizoral‘.

What is the basic strategy for the future development of Hemofarm on the Serbian market?

‘The basic mission of Hemofarm is to earn every day and hold the trust of clients, suppliers, partners on the market, as well as patients and all users of our products. Because with pride we provide products of superior quality, availability and concern for preserving and improving everybody health. One of the strategic goals of the development of Hemofarm is the constant improvement of the portfolio and continuous supply of the market with quality products of the latest generation, which are available to everyone.

I am very proud of the fact that we are ending this year with 306 million packages produced, which represents an increase of 6.8% compared to 2021. However, it is equally important for us that the Hemofarm company continues to base its activity on four key corporate values - Integrity, Entrepreneurship, Agility and One STADA. We will continue to invest intensively in the development of our employees and show by our example to others that changes for the better are always possible.‘

How important is it to motivate other companies in the country and region to follow the example of sustainable development and business of the Hemofarm company?

‘Leading by example is very important for each individual, for society as a whole. Look at it this way, you can have short-term success, using whatever resources you have, but that's nothing compared to the work of the next five, ten, twenty, years. Hemofarm has been here for 62 years, and we have many more decades of work ahead of us, and we want to continue our socially responsible path. We all live here, we want to live a good life with our families and friends, so we could leave a better planet for future generations. We at Hemofarm do this every day, every year with our personal example, which I hope others will start to follow‘, Dr. Ronald Seeliger, CEO of Hemofarm emphasized in an interview to Politika Daily.

Source: Politika